Local Anaesthetic Agents

Local Anaesthetics

Local anesthetics provide analgesia and anaesthesia by disrupting the conduction of impulses along nerve fibers. They block voltage-gated Na+, thus inhibiting the influx of sodium and preventing an action potential from being reached. They are weak bases in equilibrium (pKa > 7.4). Anaesthetics with pKa closer to physiologic pH have a greater fraction of non-ionized form (that can cross the plasma membrane) and thus have a faster onset. Conversely, in acidic environments e.g. infection, pKa is further from the environmental pH and the anaesthetic will have a slower onset.

Characteristics of Local Anaesthetics

CharacteristicAssociation
Speed of onsetpKa (degree of ionization), Concentration
PotencyLipid solubility
Duration of actionProtein binding (alpha-1 amino glycoprotein binds drug and carries it away for metabolism)

Categories of local anaesthetics

CategoryDrugsMetabolism
Amides (i before-caine)lidocaine, Bupivacaine, Ropivacaine, Mepivacaine, Etidocaine, LevobupivacaineLiver metabolism (aromatic hydroxylation, N-dealkylation, amide hydrolysis). Methylparaben used as a preservative is metabolized into PABA which can cause a small allergic-type reaction in patients.
EstersCocaine, Chloroprocaine, Procaine, TetracainePlasma pseudocholinesterase and RBC esterase (hydrolysis at ester linkage)

Amide Local Anaesthetics

AmidespKaOnsetMax dose (mg/kg)Max dose with Epinephrine (mg/kg)
Lidocaine7.9Rapid4.57
Mepivacaine7.6Medium57
Prilocaine7.9
Bupivacaine8.1Slow2.53
Ropivacaine8.1Slow1.5N/A

Ester Local Anaesthetics

EsterspKaOnsetMax dose (mg/kg)Max dose with Epi (mg/kg)
Procaine8.9
Chloroprocaine8.7Rapid1015
Tetracaine8.5Slow1.5N/A

Peripheral block Duration

Local AnaestheticDuration (hours)
Lidocaine2-4
Mepivacaine3-5
Ropivacaine5-8
Bupivacaine6-12
  • Structure of local anaesthetic Has 3 major chemical moieties
    • Lipophilic aromatic benzene ring
    • Ester or Amide linkage
    • Hydrophilic tertiary amine
  • Mechanism of action
    • Non-ionized (base, lipid-soluble) form crosses the neuronal membrane
    • Re-equilibration in axoplasm between the 2 forms
    • The ionized (cationic, water-soluble) form binds to the intracellular alpha subunit of the Na+ channel
  • Routes of administration
    • Topical
    • Intravenous
      • To inhibit inflammation
      • To decrease hemodynamic response to laryngoscopy
      • To decrease post-op pain and opioid consumption
      • Reduces MAC requirement by 40%
    • Epidural
    • Intrathecal (spinal)
    • Perineural (regional): sensory loss precedes motor weakness since small diameter A-delta myelinated nerves are most susceptible
  • Why does chloroprocaine have a fast onset despite its pKa?
    • Chloroprocaine is used in relatively higher concentrations because of its low systemic toxicity (it is rapidly metabolized by pseudocholinesterase)
  • Which is the longest acting local anaesthetic
    • Bupivacaine
  • Why is Ropivacaine preferred over Bupivacaine?
    • Has less cardiotoxicity

Local Anaesthetic Systemic Toxicity (LAST)

LAST is caused by systemic absorption at the injection site. The rate and extent of systemic absorption depend on the dose, the drug’s intrinsic pharmacokinetic properties, and the addition of vasoactive agents e.g. Epinephrine

Incidence (ICEBALLS): IV > tracheal > Intercostal > Caudal > Epidural > Brachial plexus > Axillary > Lower extremity (Sciatic/femoral) > Subcutaneous

  • CNS toxicity (readily crosses the BBB)
    • Lightheadedness, tinnitus, tongue numbness, metallic taste → CNS excitation (inhibitory pathways are blocked) → CNS depression, seizures → Coma
  • Cardiovascular toxicity (dose-dependent)
    • Bradycardia, Ventricular arrhythmia → Decreased contractility → Circulatory arrest
    Approximately 3X Local Anaesthetic is needed to produce cardiovascular toxicity than CNS toxicity Adding epinephrine allows early detection of intravascular injection and increases the maximum allowable dose
  • Which local anesthetic is the most cardiotoxic?
    • Bupivacaine: it has high binding to resting or inactivated Na+ channels and slower dissociation from these channels during diastole
    In order of ability to produce cardiotoxicity: Bupivacaine > Ropivacaine ? Lidocaine
  • Treatment of LAST
    • Stop the local anaesthetic
    • Call for help + intralipid kit
    • Supportive Treatment
      • Airway management, Breathing, and Circulatory Support
      • Circulatory support using vasopressors e.g. epinephrine, phenylephrine, and norepinephrine. Reduce individual epinephrine doses to < 1mcg/kg
      • Benzodiazepines for seizure including Midazolam 3-10mg, Diazepam 5 – 15mg, Propofol 20-60mg. Propofol and Thiopental are not not preferred due to their cardiac depressant effects.
      • Manage Arrhythmias according to ACLS protocol. Avoid Lidocaine as an anti-arrhythmic.
      • Neuromuscular blockers in case of ongoing muscle contraction due to refractory tonic-clonic movement
      • Mechanical chest compression device or a cardiac bypass may be indicated in bupivacaine-induced LAST
    • Specific Treatment: Intravenous fat emulsion therapy (acts as a lipid sink and helps redistribute the local anaesthetic away from target organs)
      • Bolus 1.5cc/kg of 20% intralipid IV (maximum of 3 boluses)
      • Infusion 0.25cc/kg/min (max rate 0.5cc/kg/min)
      • Given as simultaneous boluses and infusion based on ideal body weight.
      • After 5 minutes a second bolus can be given and the infusion rate doubled if cardiovascular stability has not returned. A 3rd and final bolus can be given after a further 5 minutes if the total maximum dose has not been reached.
  • Which medication should be avoided in case of LAST due to their cardiodepressant activity
    • VasopressinCalcium channel blockersBeta-blockersLocal anaestheticsPropofol and sodium thiopental
Reference Intervals
Biochemistry
ACTHP: <80 ng/L
ALTP: 5–35 U/L
AlbuminP: 35–50 g/L
AldosteroneP: 100–500 pmol/L
Alk. phosphataseP: 30–130 U/L
α-AmylaseP: 0–180 IU/dL
α-FetoproteinS: <10 kU/L
Angiotensin IIP: 5–35 pmol/L
ADHP: 0.9–4.6 pmol/L
ASTP: 5–35 U/L
BicarbonateP: 24–30 mmol/L
BilirubinP: 3–17 μmol/L
BNPP: <50 ng/L
CRPP: <10 mg/L
CalcitoninP: <0.1 mcg/L
Calcium (ionized)P: 1.0–1.25 mmol/L
Calcium (total)P: 2.12–2.60 mmol/L
ChlorideP: 95–105 mmol/L
CholesterolP: <5.0 mmol/L
VLDLP: 0.128–0.645 mmol/L
LDLP: <2.0 mmol/L
HDLP: 0.9–1.93 mmol/L
Cortisol AMP: 450–700 nmol/L
Cortisol MidnightP: 80–280 nmol/L
CK ♂P: 25–195 U/L
CK ♀P: 25–170 U/L
CreatinineP: 70–100 μmol/L
FerritinP: 12–200 mcg/L
FolateS: 2.1 mcg/L
FSHP: 2–8 U/L ♂; >25 menopause
GGT ♂P: 11–51 U/L
GGT ♀P: 7–33 U/L
Glucose (fasting)P: 3.5–5.5 mmol/L
Growth hormoneP: <20 mu/L
HbA1C (DCCT)B: 4–6%
HbA1C (IFCC)B: 20–42 mmol/mol
Iron ♂S: 14–31 μmol/L
Iron ♀S: 11–30 μmol/L
Lactate (venous)P: 0.6–2.4 mmol/L
Lactate (arterial)P: 0.6–1.8 mmol/L
LDHP: 70–250 U/L
LHP: 3–16 U/L
MagnesiumP: 0.75–1.05 mmol/L
OsmolalityP: 278–305 mosmol/kg
PTHP: 0.8–8.5 pmol/L
PotassiumP: 3.5–5.3 mmol/L
Prolactin ♂P: <450 U/L
Prolactin ♀P: <600 U/L
PSAP: 0–4 mcg/mL
Protein (total)P: 60–80 g/L
Red cell folateB: 0.36–1.44 μmol/L
Renin (erect)P: 2.8–4.5 pmol/mL/h
Renin (recumbent)P: 1.1–2.7 pmol/mL/h
SodiumP: 135–145 mmol/L
TBGP: 7–17 mg/L
TSHP: 0.5–4.2 mU/L
T4P: 70–140 nmol/L
Free T4P: 9–22 pmol/L
TIBCS: 54–75 μmol/L
TriglyceridesP: 0.50–2.3 mmol/L
T3P: 1.2–3.0 nmol/L
Troponin TP: <0.1 mcg/L
Urate ♂P: 210–480 μmol/L
Urate ♀P: 150–390 μmol/L
UreaP: 2.5–6.7 mmol/L
Vitamin B12S: 0.13–0.68 nmol/L
Vitamin DS: 50 nmol/L
Arterial Blood Gases
pH7.35–7.45
PaCO₂4.7–6.0 kPa
PaO₂>10.6 kPa
Base excess±2 mmol/L
Urine
Cortisol (free)<280 nmol/24h
Hydroxyindole acetic acid16–73 μmol/24h
Hydroxymethylmandelic acid16–48 μmol/24h
Metanephrines0.03–0.69 μmol/mmol cr.
Osmolality350–1000 mosmol/kg
17-Oxogenic steroids ♂28–30 μmol/24h
17-Oxogenic steroids ♀21–66 μmol/24h
17-Oxosteroids ♂17–76 μmol/24h
17-Oxosteroids ♀14–59 μmol/24h
Phosphate (inorganic)15–50 mmol/24h
Potassium14–120 mmol/24h
Protein<150 mg/24h
Protein/creatinine ratio<3 mg/mmol
Sodium100–250 mmol/24h
Haematology
WCC4.0–11.0 ×10⁹/L
RBC ♂4.5–6.5 ×10¹²/L
RBC ♀3.9–5.6 ×10¹²/L
Hb ♂130–180 g/L
Hb ♀115–160 g/L
PCV ♂0.4–0.54 L/L
PCV ♀0.37–0.47 L/L
MCV76–96 fL
MCH27–32 pg
MCHC300–360 g/L
RDW11.6–14.6%
Neutrophils2.0–7.5 ×10⁹/L (40–75%)
Lymphocytes1.0–4.5 ×10⁹/L (20–45%)
Eosinophils0.04–0.44 ×10⁹/L (1–6%)
Basophils0–0.10 ×10⁹/L (0–1%)
Monocytes0.2–0.8 ×10⁹/L (2–10%)
Platelets150–400 ×10⁹/L
Reticulocytes0.8–2.0% / 25–100 ×10⁹/L
Prothrombin time10–14 s
APTT35–45 s
Paediatric
Pulse Rate (bpm)
Neonate140–160
Infant <1yr120–140
1–5 years110–130
5–12 years80–120
>12 years70–100
Respiratory Rate (tachypnoea)
0–2 months≥60/min
2–12 months≥50/min
1–5 years≥40/min
>5 years≥30/min
Blood Pressure (mmHg)
Term65/45
1 year75/50
4 years85/60
8 years95/65
10 years100/70
Weight Formulas
3–12 months(a + 9)/2 kg
1–6 years2a + 8 kg
>6 years(7a − 5)/2 kg
Haemoglobin (g/dL)
Term newborn13–20
1 month11–18
2 months10–15
1–2 years10–13
>2 years11–14
MUAC (6 months–5 years)
Obese>17.5 cm
Normal13.5–17.4 cm
At risk12.5–13.4 cm
Moderate malnutrition11.5–12.4 cm
Severe malnutrition<11.5 cm
Developmental Milestones
Social smile1.5 months
Head control4 months
Sits unsupported7 months
Crawls10 months
Stands unsupported10–12 months
Walks12–13 months
Talks18 months
CSF WBC (/mm³)
Term newborn0–25
>2 weeks0–5
Calculator

Post Discussion

Your email address will not be published. Required fields are marked *